Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experience
Abstract Introduction In the European Union (EU), a Risk Management Plan (RMP) is submitted as part of the dossier for initial marketing authorization of a medicinal product or with an application involving a significant change to an existing marketing authorization. A comprehensive revision of the...
Saved in:
Main Authors: | Suzan Esslinger (Author), Linda Quinn (Author), Sami Sampat (Author), Marijo Otero-Lobato (Author), Wim Noël (Author), Anja Geldhof (Author), Nicole Herijgers (Author), Sarah-Jane Reeder (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exposure to golimumab during pregnancy: Results from the Company's global safety database
by: Marijo Otero‐Lobato, et al.
Published: (2024) -
Effectiveness of the golimumab educational program in ensuring healthcare professionals' awareness of risks described in the European risk management plan
by: Lauren Felo, et al.
Published: (2019) -
In good company
by: Kernahan, Coulson, 1858-1943 -
Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice
by: N. Yu. Velts, et al.
Published: (2023) -
Tracking global resources and capacity for health research: time to reassess strategies and investment decisions
by: Taghreed Adam, et al.
Published: (2023)